LARGE CO.can do it better-MYTH---- Small co.do far better.
I know DNDN and SVNT well. You can be Biotech.--but if your product is not good enough against competition.(REMEMBER the phrase-- Changing Competition).
MDVN and others did DNDN in. SVNT product Krystexxa did not measure up.
The CEO of SVNT was terrible --lost lot of money.
KEY to a Successful BioTech.firm:
Bring in Professional managers.
I analyzed Genentech in 1980 as we were asked to invest 20 mil.$.During our trip-what impressed me most was that they hired Abbott CEO. Genentech had 3 good products--but getting them to market place profitably was not the job of R&D types.
We did invest 20 mil.$.
I always look for top managers experience. I am satisfied with PAUL HUFF's credentials who can do a good job of execution in USA. Not sure about his abilities for OUTSIDE US.
By the way,I own MDVN
I respectfully disagree. For openers, there was only one Genentech. I am in Industry,
and can assure you that the number of feet on the ground (Reps) for statin Co's MRK, PFE,
AZN dwarf what a small Biotech can approximate. The above mentioned Reps have had relatioships with Cardiologists, and Primary Care Doc's for mor than a decade. They can
get right through the door andmarket Vascepa.
AZN is big in Gastrointestinal area and I know someone who has lectured on Nexium .But AZN was unknown in Cardiology field--when they launched Crestor. Their sales force did a great job.But Jupiter study did wonders-- they found a subgroup that resonded better to Crestor-they got FDA in 2009 to approve NEW labeling--Sales soared from 4.5 bil.to 6.5 bil. in 2 years.